Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
News: Nos articles
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
The feature you requested does not exist. However, we suggest the following feature:

Novavax : says vaccine is 94.1% effective in Phase 3 trial

06/14/2021 | 09:09am EDT

Maryland-based Novavax said Monday that its COVID-19 vaccine is 90.4% effective overall in a Phase 3 study conducted in the United States and Mexico, including 93% against predominant variants.

The company said the study of 29,960 participants, which is ongoing, showed the vaccine is 91% against high-risk populations, such as the elderly and those with compromised immune systems.

"Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines," company CEO Stanley C. Erck said in a statement.

"Novavax continues to work with a sense of urgency to complete our regulatory submissions and deliver this vaccine, built on a well understood and proven platform, to a world that is still in great need of vaccines."

Novavax said it plans to file for regulatory authorizations in the third quarter once its final phases of process qualification needed to meet chemistry, manufacturing and controls requirements are completed.

Once approved, Novavax said it can produce 100 million doses of the vaccine per month and 150 million doses per month by the end of the year.

"These data show consistent, high levels of efficacy and reaffirm the ability of the vaccine to prevent COVID-19 amid ongoing genetic evolution of the virus," Dr. Gregory M. Glenn, president ofNovavax's research and development said in a statement.

"Our vaccine will be a critical part of the solution to COVID-19 and we are grateful to the study participants and trial staff who made this study possible, as well as our supporters, including the U.S. government," Glenn said.

Copyright 2021 United Press International, Inc. (UPI). Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent., source US Top News

Latest news "Nos articles"
06:25aANALYST RECOMMENDATIONS : Alliant Energy, Ally Financial, Alphabet, HSBC, Honest...
06/11Today on Wall Street: Much ado about nothing
06/11ANALYST RECOMMENDATIONS : Brown-Forman, Casey's General Stores, GameStop, Reckitt Benckiser, RH...
06/10Global markets live: Tesla, BT Group, GameStop, Alibaba, Boeing...
06/10Today on Wall Street: Prices rise faster than expected in May
06/10ANALYST RECOMMENDATIONS : Ally Financial, Delta Air Lines, IAG, ServiceNow, United Parcel Service...
06/09BRITISH POUND / US DOLLAR (GBP/USD)á : British Pound/US Dollar (GBP/USD): Currencies: a forward-looking pound
06/09GLOBAL MARKETS LIVE : Amazon, Berkshire Hathaway, Robinhood, Fastly...
06/09Today on Wall Street: The day before tomorrow
06/09ANALYST RECOMMENDATIONS : APA, Bank of America, Citigroup, Goldman Sachs, Visa...
Latest news "Nos articles"